377 related articles for article (PubMed ID: 10756965)
1. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method].
Rüffert H; Olthoff D; Deutrich C; Thamm B; Froster U
Anaesthesist; 2000 Feb; 49(2):113-20. PubMed ID: 10756965
[TBL] [Abstract][Full Text] [Related]
2. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
Rueffert H; Olthoff D; Deutrich C; Froster UG
Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
[TBL] [Abstract][Full Text] [Related]
3. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
5. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
[TBL] [Abstract][Full Text] [Related]
6. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
[TBL] [Abstract][Full Text] [Related]
7. [Current aspects of the diagnosis of malignant hyperthermia].
Rüffert H; Olthoff D; Deutrich C; Froster UG
Anaesthesist; 2002 Nov; 51(11):904-13. PubMed ID: 12434264
[TBL] [Abstract][Full Text] [Related]
8. Homozygous and heterozygous Arg614Cys mutations (1840C-->T) in the ryanodine receptor gene co-segregate with malignant hyperthermia susceptibility in a German family.
Rueffert H; Olthoff D; Deutrich C; Thamm B; Froster UG
Br J Anaesth; 2001 Aug; 87(2):240-5. PubMed ID: 11493496
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Mortier W; Breucking E
Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
[TBL] [Abstract][Full Text] [Related]
10. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families.
Heytens L
Acta Anaesthesiol Belg; 2007; 58(2):113-8. PubMed ID: 17710899
[TBL] [Abstract][Full Text] [Related]
12. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
[TBL] [Abstract][Full Text] [Related]
13. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J
J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940
[TBL] [Abstract][Full Text] [Related]
14. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
15. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
[TBL] [Abstract][Full Text] [Related]
16. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test.
Brandt A; Schleithoff L; Jurkat-Rott K; Klingler W; Baur C; Lehmann-Horn F
Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775
[TBL] [Abstract][Full Text] [Related]
17. Screening for mutations in the RYR1 gene in families with malignant hyperthermia.
Muniz VP; Silva HC; Tsanaclis AM; Vainzof M
J Mol Neurosci; 2003; 21(1):35-42. PubMed ID: 14500992
[TBL] [Abstract][Full Text] [Related]
18. North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.
Sambuughin N; Sei Y; Gallagher KL; Wyre HW; Madsen D; Nelson TE; Fletcher JE; Rosenberg H; Muldoon SM
Anesthesiology; 2001 Sep; 95(3):594-9. PubMed ID: 11575529
[TBL] [Abstract][Full Text] [Related]
19. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
[TBL] [Abstract][Full Text] [Related]
20. Malignant hyperthermia susceptibility, an autosomal dominant disorder?
Fagerlund TH; Islander G; Ranklev Twetman E; Berg K
Clin Genet; 1997 Jun; 51(6):365-9. PubMed ID: 9237497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
